Utilizing autologous induced pluripotent stem cells (iPSCs) combined with 3D bioprinting technology, the company’s engineered follicular units (EFUs) successfully integrated into humanized skin models and generated fully developed, cycling human hair follicles. This historic advancement paves the way for the first human clinical trials of bioengineered hair cloning, promising an unlimited supply of donor hair for patients with advanced baldness.
What Is It and How Does It Work?
Stemson Therapeutics’ platform is an autologous cell therapy that uses a small sample of a patient’s own skin or blood cells. These cells are turned back into “blank slate” induced pluripotent stem cells (iPSCs) before being converted into specialized hair-building cells.
The treatment works through a cutting-edge process of Autologous iPSC Reprogramming and 3D Bioprinting of Follicular Units:
-
Dual Cell Lineage Creation: Patient skin cells are reprogrammed into two distinct cell types essential for hair creation: epithelial stem cells (which build the hair shaft and sheath) and dermal papilla cells (which send growth signals).
-
3D Bioprinted Scaffolding: Using a proprietary biomaterial, Stemson bioprints these two cell types into a microscopic 3D structure called an Engineered Follicular Unit (EFU) that mimics the embryonic “hair germ”.
-
De Novo Follicle Formation: When implanted into the scalp, these bioprinted units interact with the surrounding skin, connect to local blood vessels, and mature into brand-new, fully functional hair follicles capable of naturally growing, shedding, and regenerating hair over a lifetime.
Because the cells are derived from the patient’s own tissue (autologous), the newly grown hair follicles are genetically identical to the patient’s natural hair and carry zero risk of immune rejection.
The Science: De Novo Human Follicle Growth in Humanized Models
The preclinical results mark a crucial step forward from earlier animal studies. Previously, bioengineering hair required mixing human cells with mouse cells to trigger growth. Stemson’s latest breakthrough proved that an all-human cell solution can successfully form complete human hair follicles.
Key scientific highlights include:
-
100% Human Cell Integration: iPSC-derived human epithelial and dermal cells bioprinted into EFUs successfully grew mature human hair follicles in human skin explants grafted onto animal models.
-
Sustaining Inductive Power: Cultured human hair cells typically lose their ability to grow hair within a few days in a lab. Stemson’s 3D bioprinting environment preserved the cells’ natural Wnt/$\beta$-catenin signaling pathways, maintaining their hair-inductive power.
-
Unlimited Donor Supply: Traditional hair transplants (FUE or FUT) are strictly limited by the amount of healthy donor hair available at the back of a patient’s head. By expanding iPSCs in a laboratory, this cell therapy offers a virtually unlimited supply of new hair roots from a single skin sample.
“Growing hair using an all-human cell solution on human skin is an incredible advancement in cell therapy. It sets up the platform to move through clinical trials and brings us closer to solving the limitation of donor hair supply once and for all.” — Stemson Therapeutics Scientific Research Team.
When Will It Be Available?
-
Current Stage: Stemson Therapeutics has completed preclinical proof-of-concept testing and is conducting IND-enabling safety and manufacturing studies.
Read next
Whats the best shampoo for hair loss?
-
Timeline: The company is advancing toward initiating its Phase 1 human clinical trials. Because bioengineered cell therapies require extensive long-term safety evaluation, commercial availability for hair cloning procedures is projected for the 2030s.
How you can benefit from this treatment now
While iPSC-derived bioengineered hair cloning completes its transition into human clinical trials, you can take practical steps to prepare for and benefit from regenerative hair science today:
-
Consider Follicle Banking: Cryopreservation services (such as HairClone in the UK) allow individuals to freeze and store healthy hair follicles today. Preserving your young dermal papilla cells now ensures they can be expanded and multiplied when cell-cloning therapies become commercially available.
-
Explore Autologous Secretome Therapies: Patients seeking regenerative therapies today can look into autologous stem cell secretome or PRP treatments. These therapies harvest growth factors and exosomes from your existing hair roots or blood to reactivate dormant follicles while full cell-cloning transplants undergo trial testing.
-
Optimize Existing Donor Density: If you require immediate coverage for advanced hair loss, modern FUE hair transplants integrated with biological holding solutions (such as Ampligraf) remain the evidence-based gold standard for structural restoration.
Sources: